<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is estimated to affect 1%-2% of the population </plain></SENT>
<SENT sid="1" pm="."><plain>It is increasing in prevalence and is associated with excess mortality, considerable morbidity and hospitalisations </plain></SENT>
<SENT sid="2" pm="."><plain>AF is responsible for a significant and growing societal financial burden </plain></SENT>
<SENT sid="3" pm="."><plain>Catheter ablation is an increasingly used therapeutic strategy for the management of AF; however, some <z:hpo ids='HP_0001289'>confusion</z:hpo> exists among those caring for patients with this condition about the role and optimal use of ablative treatments for AF </plain></SENT>
<SENT sid="4" pm="."><plain>Our aim in this consensus statement is to provide recommendations on the use of primary catheter ablation for AF in Australia, on the basis of current evidence </plain></SENT>
<SENT sid="5" pm="."><plain>Our consensus is that the primary indication for catheter ablation of AF is the presence of symptomatic AF that is refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication </plain></SENT>
<SENT sid="6" pm="."><plain>In selecting patients for catheter ablation of AF, consideration should be given to the patient's age, duration of AF, left atrial size and the presence of significant structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Best results are obtained in younger patients with paroxysmal AF, no structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and smaller atria </plain></SENT>
<SENT sid="8" pm="."><plain>Ablation techniques for patients with persistent AF are still undergoing evaluation </plain></SENT>
<SENT sid="9" pm="."><plain>Discontinuation of <z:chebi fb="8" ids="10033">warfarin</z:chebi> or equivalent therapies is not considered a sole indication for this procedure </plain></SENT>
<SENT sid="10" pm="."><plain>After AF ablation, anticoagulation therapy is generally recommended for <z:hpo ids='HP_0000001'>all</z:hpo> patients for at least 1-3 months </plain></SENT>
<SENT sid="11" pm="."><plain>Discontinuation of <z:chebi fb="8" ids="10033">warfarin</z:chebi> or equivalent therapies after ablation is generally not recommended in patients who have a CHADS 2 score (<z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, age ≥ 75 years, <z:mp ids='MP_0002055'>diabetes</z:mp>, 1 point each; prior <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:e sem="disease" ids="C0007787" disease_type="Disease or Syndrome" abbrv="tia|TIA|T.I.A.">transient ischaemic attack</z:e>, 2 points) of ≥ 2 </plain></SENT>
</text></document>